Adrenalitis and anasarca in idiopathic multicentric Castleman's disease

被引：0
|
作者：
Chen, Luke Y. C. [1 ,2 ]
Skinnider, Brian F. [3 ]
Wilson, Don [4 ,5 ]
Fajgenbaum, David C. [6 ]
机构：
[1] Univ British Columbia, Div Haematol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Ctr Hlth Scholarship, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada
[5] British Columbia Canc Agcy, Vancouver Ctr, Funct Imaging Program, Vancouver, BC, Canada
[6] Univ Penn, Perelman Sch Med, Ctr Cytokine Storm Treatment & Lab, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA
来源：
LANCET | 2021年 / 397卷 / 10286期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1749 / 1749
页数：1
相关论文
共 50 条
  • [21] Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto, Shino
    Sakai, Tomoyuki
    Kawabata, Hiroshi
    Kurose, Nozomu
    Yamada, Sohsuke
    Takai, Kazue
    Aoki, Sadao
    Kuroda, Junya
    Ide, Makoto
    Setoguchi, Keigo
    Tsukamoto, Norifumi
    Iwao-Kawanami, Haruka
    Kawanami, Takafumi
    Mizuta, Shuichi
    Fukushima, Toshihiro
    Masaki, Yasufumi
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (09) : 975 - 983
  • [22] Idiopathic multicentric Castleman disease: bringing order to chaos
    Leitch, Heather A.
    LANCET HAEMATOLOGY, 2020, 7 (03): : E180 - E181
  • [23] Targeting the mTOR pathway in idiopathic multicentric Castleman disease
    Stern, Robert M.
    Berliner, Nancy
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10): : 4086 - 4088
  • [24] Increased mTOR activation in idiopathic multicentric Castleman disease
    Arenas, Daniel J.
    Floess, Katherine
    Kobrin, Dale
    Pai, Ruth-Anne Langan
    Srkalovic, Maya B.
    Tamakloe, Mark-Avery
    Rasheed, Rozena
    Ziglar, Jasira
    Khor, Johnson
    Parente, Sophia A. T.
    Pierson, Sheila K.
    Martinez, Daniel
    Wertheim, Gerald B.
    Kambayashi, Taku
    Baur, Joseph
    Teachey, David T.
    Fajgenbaum, David C.
    BLOOD, 2020, 135 (19) : 1673 - 1684
  • [25] Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
    Fajgenbaum, David C.
    Kurzrock, Razelle
    IMMUNOTHERAPY, 2016, 8 (01) : 17 - 26
  • [26] Cytokine pathways in the pathogenesis of idiopathic Multicentric Castleman Disease
    Uhlfelder, D.
    Schaefer, H.
    Blanfeld, M.
    Andruszewski, D.
    Schelmbauer, C.
    Gaida, M.
    Waisman, A.
    Mufazalov, I
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 136 - 136
  • [27] How We Manage Idiopathic Multicentric Castleman Disease
    Brandstadter, Joshua D.
    Fajgenbaum, David C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) : 564 - 571
  • [28] Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
    Pierson, Sheila K.
    Kanhai, Karan
    Bagg, Adam
    Alapat, Daisy
    Lim, Megan S.
    Lechowicz, Mary Jo
    Srkalovic, Gordan
    Uldrick, Thomas S.
    van Rhee, Frits
    Fajgenbaum, David C.
    BLOOD, 2021, 138
  • [29] Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
    Yamamoto, Yu
    Matsumura, Masami
    CLINICAL CASE REPORTS, 2021, 9 (05):
  • [30] Multicentric Castleman's disease in Malawi
    Gopal, Satish
    Fedoriw, Yuri
    Montgomery, Nathan D.
    Kampani, Coxcilly
    Krysiak, Robert
    Sanders, Marcia K.
    Dittmer, Dirk P.
    Liomba, N. George
    LANCET, 2014, 384 (9948): : 1158 - 1158
12345